DMTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, DermTech's PE Ratio without NRI is 0.00. DermTech's 5-Year EBITDA growth rate is -80.70%. Therefore, DermTech's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for DermTech's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for DermTech's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DermTech Annual Data | |||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
DermTech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, DermTech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where DermTech's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
DermTech's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | -80.70 | ||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
DermTech (NAS:DMTK) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of DermTech's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin M Sun | officer: Chief Financial Officer | 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121 |
Claudia Ibarra | officer: Chief Operating Officer | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Ramin Akhavan | officer: General Counsel | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Mark Bryan Aguillard | officer: Chief Commercial Officer | 19800 CORDILL LANE, SPICEWOOD TX 78669 |
Todd Michael Wood | officer: Chief Commercial Officer | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008 |
Bret Christensen | director, officer: Chief Executive Officer | 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
John Dobak | director, officer: Chief Executive Officer | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Kirk Malloy | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Mark Christopher Capone | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Herm Rosenman | director | OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ |
Nathalie Gerschtein Keraudy | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Monica Tellado | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Enrico Picozza | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 12-14-2023
By PRNewswire • 11-17-2023
By ACCESSWIRE • 12-04-2023
By PRNewswire • 11-22-2023
By PRNewswire • 11-21-2023
By PRNewswire • 12-06-2023
By Business Wire • 12-13-2023
By Business Wire • 01-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.